Crisaborole (Eucrisa) ointment received FDA approval to treat mild to moderate eczema (atopic dermatitis) in patients aged 2 years and older.
Friday, January 20, 2017
Wednesday, February 25, 2015
Researchers who conducted a longitudinal cohort study, published in JAMA Dermatology1 online ahead of print, concluded that “it seems unlikely that topical pimecrolimus as it was used in the Pediatric Eczema Elective Registry (PEER) cohort to treat atopic dermatitis is associated with an increased risk of malignancy.”
Monday, June 15, 2009
Research highlights and trends in treating pediatric dermatology conditions. TRENDS IN PEDIATRIC S. AUREUS HEAD AND NECK INFECTIONS Seeking to evaluate the epidemiologic manifestations of pediatric Staphylococcus aureus head and neck infections nationwide and to identify possible trends in the antibiotic drug susceptibility of S. aureus during a 6-year period, researchers conducted a retrospective review of microbiologic data from a peer-reviewed national database. The researchers, Iman Naseri, MD, Robert C. Jerris, PhD, and Steven E. Sobol, MD, MSc, reviewed data on all
Monday, December 8, 2008
Reading the annual Year-in-Review CME article, it’s obvious that dermatology has seen another year with great advances. Dr. Christopher B. Yelverton offers a review of new and pertinent knowledge of the pathophysiology and treatment of a variety of skin conditions as well as regulatory developments that will affect your practice in the coming year. Here are some highlights from this must-read article. • MRSA continues to be a major health threat to communities across the country. Dr. Yelverton highlights research that has shown “the potential importance of phenol-soluble modulins (PSM) in
Thursday, September 4, 2008
Patient Presentation A 33-year-old pregnant woman, gravida one, para zero, presented at 34 weeks of gestation complaining of a progressively worsening pruritic eruption. The lesions began around her umbilicus, and over a few days, extended to involve her whole abdomen with extension to her lower extremities. She was otherwise healthy with no personal or family history of any skin diseases. Her current list of medications included only iron supplements and prenatal vitamins. On physical examination, multiple erythematous papules and plaques were noted on her abdomen and upper thighs. Th
Thursday, September 4, 2008
In this third part of my series on cosmetics, drugs and cosmeceuticals, I will discuss the following: • how a product's intended use is established • various cosmeceutical products whose claims have caused them to run afoul of the law • how approval requirements differs for drugs and cosmetics • the definition of a new drug application • the definition of a monograph (as it applies to over-the-counter drug categories such as sun blocks) •definitions of new drugs. Much of the technical da
Wednesday, December 14, 2016
The FDA recently announced its approval of Pfizer Inc's ointment, crisaborole (Eucrisa), to treat mild to moderate cases of the itchy skin condition eczema, or atopic dermatitis, for use in patients aged two years and older.
Tuesday, September 6, 2016
Babies given antibiotics in the first two years of life are more likely to develop allergies as adults, according to an extensive analysis of past clinical studies involving nearly 400,000 people.
Friday, July 15, 2016
Crisaborole ointment demonstrated a favorable safety profile and improvement in all measures of efficacy, for the topical treatment of atopic dermatitis.
Friday, March 13, 2015
All three products in its newest product line, CeraVe Baby (Valeant Pharmaceuticals North America LLC) have been awarded the National Eczema Association (NEA) Seal of Acceptance, which maintains rigorous standards for approval. Three-step skincare regimen was developed with pediatric dermatologists to help protect and maintain the skin barrier of babies.